IPCALAB.NS
IPCALAB.NS
INE571A01038
IPCA LABORATORIES LTD
Loading chart...

Company Profile

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/protectives, fever, gastroenterology, haematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, regenerative, respiratory, rheumatology, and urology. The company also exports its products to Europe, Africa, the Americas, rest of Asia, the Commonwealth of Independent States, and Australasia. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

Related stocks

ABBOTINDIA.NS
ABBOTINDIA.NS • India
ABBOTT INDIA LIMITED
26,000 INR
5.71B USD 1Y -14.5%
AJANTPHARM.NS
AJANTPHARM.NS • India
AJANTA PHARMA LIMITED
3,410.1 INR
4.4B USD 1Y +40.8%
EMCURE.NS
EMCURE.NS • India
EMCURE PHARMACEUTICALS L
1,833.5 INR
3.59B USD 1Y +31.4%
GLENMARK.NS
GLENMARK.NS • India
GLENMARK PHARMACEUTICALS
2,293 INR
6.69B USD 1Y +13.6%
ALKEM.NS
ALKEM.NS • India
ALKEM LABORATORIES LTD.
5,279 INR
6.52B USD 1Y -4.4%
AUROPHARMA.NS
AUROPHARMA.NS • India
AUROBINDO PHARMA LTD
1,693 INR
10.07B USD 1Y +51.2%
LUPIN.NS
LUPIN.NS • India
LUPIN LIMITED
1,956.5 INR
9.24B USD 1Y -0.1%
CIPLA.NS
CIPLA.NS • India
CIPLA LTD
1,301 INR
10.86B USD 1Y -14%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
28.1% p.a.
Max Drawdown (5Y)
-44.3%
Sharpe Ratio (5Y)
0.27
Beta Factor
0.04
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (28.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -48.8% in the extended horizon.
ende